Syncona, UCLB form cancer immunotherapy firm Autolus

Syncona and UCL Business, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours.

Category One, Showcase, status, Uncategorized, What's Hot